Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada

REFERENCES

• PaleIla FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–58.
   PubMed Web of Science ®Google Scholar
• Karmon SL, Moore RD, Dobs AS, Keruly J, et al. Body shape and composition in HIV-infected women: an urban cohort. HIV Med. 2005;6:245–252.
   PubMed Web of Science ®Google Scholar
• Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19\(suppl 4):514–521.
   Google Scholar
• Huang JS, Harrity S, Lee D, Becerra K, Santos R, Mathews WC. Body image in women with HIV: a cross-sectional evaluation. AIDS Res Ther 2006;3:17.
   PubMedGoogle Scholar
• Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm lnfec. 2003;79:137–141.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001; 28(5):445–449.
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32(1):48–56.
   PubMed Web of Science ®Google Scholar
• Visnegarwala F, et al. SMART Study, CPCRA 065: Racial differences in the prevalence of self reported changes in body habitus and their association with body composi-tion measurements in a cohort of HIV +ve patients for the Terry Beirn Community Programs for clinical research on AIDS (CPCRA) and the SMART Team. Presented at: The XV International AIDS Conference; 2004. Poster WePeB5931.
   Google Scholar
• Heath KV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231–239.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Law M, El-Sadr W, Carr A. Ethnic differ-ences in objective measures of lipodystrophy. Presented at: The XV International AIDS Conference; 2004. Abstract WePeB5939.
   Google Scholar
• Galli M, Veglia F, Angarano G, Santambrogio S, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Synd. 2003;34(1):58–61.
   PubMed Web of Science ®Google Scholar
• Jacobsen DL, Knox T, Spiegelman D, Skinner S, Gor-bach S, Wanke C. Prevalence of, evolution, of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. HIV/AIDS Clin Infect Dis. 2005;40:1837–1845.
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Raboud JR, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to cor-rect facial lipoatrophy in HIV-positive patients. AIDS. 2007;21(9)1147–1155.
   Web of Science ®Google Scholar
• Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender: differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008;47(4):441–448.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmaco-kinetic profile: a review of sex differences. Gend Med. 2007;4(2):106–119.
   PubMed Web of Science ®Google Scholar
• UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. The Joint United Nations Program on HIV/AIDS and the World Health Organization. http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. Accessed January 21,2011.
   Google Scholar
• Public Health Agency of Canada. Summary: Estimates of HIV Prevalence and Incidence in Canada, 2008. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada. http://www.phac-aspc.gc.ca/aids-sida/publication/survre-port/pdf/estimat08-eng.pdf. Accessed January 21,2011.
   Google Scholar
• The Outcomes Committee for the AIDS Clinical Trials Group (ACTG). Quality of Life Forms: Baseline Body Image Questionnaire - Form QL0720.1998. https://www.fstrf.org/apps/cfmx/apps/actg/html/QOLForms/index.html. Accessed August 14, 2010.
   Google Scholar
• Tran C, Knowles SR, Liu BA, Shear NH. Gender dif-ferences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003–1009.
   PubMed Web of Science ®Google Scholar
• Hawkins, T. Appearance-related side effects of HIV-1 treat-ment. AIDS Patient Care STDs. 2006;20(1):6–18.
   PubMed Web of Science ®Google Scholar
• Chen D, Misra A, Garg A. Lipodystrophy in Human Immu-nodeficiency Virus-infected patients. J Clin Endocrinol Metab. 2002;87(11):4845–4856.
   PubMed Web of Science ®Google Scholar
• Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care. 2007;30(1)113–119.
   Web of Science ®Google Scholar
• Haugaard SB, Andersen O, Helsell I, Iversen J, Hales CN, Madsbad S. Impaired pro-insulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metab Clin Exp. 2007;56: 939–946.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrionol Metab. 2004;286:E261–E271
   Web of Science ®Google Scholar
• Duong M, Petit JM, Martha B, et al. Concentration of cir-culating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials. 2006;7(2):41–47.
   PubMed Web of Science ®Google Scholar
• Tien PC, Cole SR, Masters Williams C, et al. Incidence of lipoatrophy in the women's interagency HIV Study. J Acquir Immune Defic Syndr 2003;34:461–466.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006;41(5):590–597.
   PubMed Web of Science ®Google Scholar
• Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials. 2001;2(4):339–345.
   PubMedGoogle Scholar
• Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection. 2002;30(5): 293–298.
   PubMed Web of Science ®Google Scholar
• Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2(3):174–180.
   PubMedGoogle Scholar
• Baril JG, Junod P, Leblanc R, et al. HIV-associated lipodys-trophy syndrome: a review of clinical aspects. Can J Infect Dis Med Microbiol. 2005 ;16(4):233–243.
   PubMedGoogle Scholar
• Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002;3(1):49–55.
   PubMedGoogle Scholar
• Lichtenstein KA, Ward DJ, Moorman AC, et al; and the HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389–1398.
   PubMed Web of Science ®Google Scholar
• Forrester JE, Gorbach SL. Fat distribution in relation to drug use, human immunodeficiency virus (HIV) status, and the use of antiretroviral therapies in Hispanic patients with HIV infection. Clin Infect Dis. 2003;37(Suppl 2): S62–S68.
   Google Scholar
• Galli M, Ridolfo AL, Adorni F, et al. Correlates of risk of adi-pose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther 2003;8(4):347–354.
   PubMed Web of Science ®Google Scholar
• Glass TR, Battegay M, Cavassini M, et al. Longitudi-nal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010;54(2)1 97–203.
   Web of Science ®Google Scholar
• Van der Valk M, Gisolf EH, Reiss P, et al; for the Pro-metheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 200115: 847–855.
   Google Scholar
• Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mito-chondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials. 2008;9(6):407–417.
   PubMed Web of Science ®Google Scholar
• Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy; a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007;8(5):337–344.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials. 2005;6(6):337–343.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Rosenbaum KB, Wang J, Pierson RN. Altera-tions in body fat distribution in HIV-infected men and women. In: Program and Abstracts of the 12th World AIDS Conference; June 28 - July 3,1998; Geneva, Switzerland. Abstract 32173.
   Google Scholar
• Tungsiripat M, O'Riordan MA, Storer N, et al. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials. 2009;10(5): 314–319.
   PubMed Web of Science ®Google Scholar